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ABSTRACT 
An impurity in a drug substance as defined by the International Conference on Harmonisation (ICH) guidelines is any component of the drug substance that is 
not the chemical entity defined as the drug substance. Similarly, an impurity in a drug product is any component of the drug product that is not the chemical 
entity defined as the drug substance or an excipient in the drug product. Genotoxic compounds have the potential to damage DNA at any level of exposure and 
that such damage may lead/contribute to tumour development. Thus for genotoxic carcinogens it is prudent to assume that there is no discernible threshold and 
that any level of exposure carries a risk.  A threshold of toxicological concern (TTC) value of 1.5μg/day intake of a genotoxic impurity is considered to be 
associated with an acceptable risk (excess cancer risk of <1 in 100,000 over a lifetime) for most pharmaceuticals. From this threshold value, a permitted level 
in the active substance can be calculated based on the expected daily dose. Higher limits may be justified under certain conditions such as short-term exposure 
periods. 
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INTRODUCTION 
Genotoxic compounds have the potential to damage DNA at 
any  level  of  exposure  and  that  such  damage  may 
lead/contribute to tumour development. A general concept of 
qualification of impurities is described in the guidelines for 
active  substances  (Q3A,  Impurities  in  New  Active 
Substances) or medicinal products (Q3B, Impurities in New 
Medicinal Products), whereby qualification is defined as the 
process of acquiring and evaluating data that establishes the 
biological  safety  of  an  individual  impurity  or  a  given 
impurity  profile  at  the  level(s)  specified.  In  the  case  of 
impurities  with  a  genotoxic  potential,  determination  of 
acceptable  dose  levels  is  generally  considered  as  a 
particularly critical issue, which is not specifically covered by 
the existing guidelines. 
In  the  current  context  the  classification  of  a  compound 
(impurity)  as  genotoxic  in  general  means  that  there  are 
positive  findings  in  established  in  vitro  or  in  vivo 
genotoxicity  tests  with  the  main  focus  on  DNA  reactive 
substances  that  have  a  potential  for  direct  DNA  damage. 
Isolated  in  vitro  findings  may  be  assessed  for  in  vivo 
relevance  in  adequate  follow-up  testing.  In  the  absence  of 
such  information  in  vitro  genotoxicants  are  usually 
considered as presumptive in vivo mutagens and carcinogens. 
A TTC value of 1.5μg/day intake of a genotoxic impurity is 
considered to be associated with an acceptable risk (excess 
cancer  risk  of  <1  in  100,000  over  a  lifetime)  for  most 
pharmaceuticals. From this threshold value, a permitted level 
in  the  active  substance  can  be  calculated  based  on  the 
expected  daily  dose.  Higher  limits  may  be  justified  under 
certain conditions such as short-term exposure periods. The 
safety  of  a  drug  product  is  dependent  not  only  on  the 
toxicological  properties  of  the  active  drug  substance  itself, 
but  also  on  the  impurities  that  it  contains.  Therefore, 
identification, quantification, and control of impurities in the 
drug  substance  and  drug  product,  are  an  important  part  of 
drug development and regulatory assessment. ICH Q3A and 
Q3B address issues relevant to the regulation of impurities in 
the  drug  substance  and  drug  product and relulation  on  the 
genotoxic  impurities.  When  more  than  one  genotoxic 
impurity is present in the drug substance, the TTC value of 
1.5μg/day can be applied to each individual impurity only if 
the impurities are structurally unrelated.
 
In  case  of  structural  similarity,  it  can  be  assumed  that  the 
impurities act by the same genotoxic mode of action and have 
the same molecular target and thus might exert effects in an 
additive manner. In such a situation, a limitation of the sum 
of  the  genotoxic  impurities  at  1.5μg/day  is  recommended. 
This  might  be  practically  not  achievable  with  reasonable 
efforts in particular when the maximum daily dose is very 
high and thus may demand application of lower group limits. 
Justifications should be made on a case-by-case basis taking 
into consideration issues such as: 
·  Maximum daily dose of the active substance; 
·  Therapeutic indication; 
·  Step of the synthesis at which the genotoxic impurity (ies) 
arises; 
·  Capability  of  the  manufacturing  process  (purification 
steps) to eliminate these impurities; 
·  Capability  of  the  analytical  procedure  to  control  these 
impurities; 
In  cases  where  routine  use  of  more  powerful  detection 
methods would be difficult, one could consider using such 
methods  during  development  or  testing  of  the  first 
commercial batches, in order to demonstrate that the actual 
values are sufficiently below the TTC. In such a case, skip 
testing  could  be  considered  instead  of  routine  testing, 
providing  that  the  Competent  Authorities,  based  on  a  risk 
assessment, consider the approach as acceptable
1,2. 
MATERIALS AND METHODS 
The  secondary  data  used  in  the  study  was  obtained  from 
various  official  reports  published  by  World  Health 
Organization and internet. The study is of descriptive type 
and method used is the description. 
TOXICOLOGICAL BACKGROUND 
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such  damage  may  lead/contribute  to  tumour  development. 
Thus for genotoxic carcinogens it is prudent to assume that 
there  is  no  discernible  threshold  and  that  any  level  of 
exposure  carries  a  risk.    However,  the  existence  of 
mechanisms  leading  to  biologically  meaningful  threshold 
effects  is  increasingly  acknowledged  also  for  genotoxic 
events.  This  holds  true  in  particular  for  compounds 
interacting  with  non-DNA  targets  and  also  for  potential 
mutagens, which are rapidly detoxified before coming into 
contact with critical targets. The regulatory approach to such 
chemicals can be based on the identification of a critical no-
observed-effect level (NOEL) and use of uncertainty factors. 
Even for compounds which are able to react with the DNA 
molecule,  extrapolation  in  a  linear  manner  from  effects  in 
high-dose studies to very low level (human) exposure may 
not  be  justified  due  to  several  protective  mechanisms 
operating effectively at low doses. However, at present it is 
extremely difficult to experimentally prove the existence of 
threshold for the genotoxicity of a given mutagen. Thus, in 
the absence of appropriate evidence supporting the existence 
of a threshold for a genotoxic compound making it difficult 
to define a safe dose it is necessary to adopt a concept of a 
level of exposure that carries an acceptable risk
3. 
GENOTOXIC IMPURITES CREATION 
Organic  impurities  can  arise  during  the  manufacturing 
process and/or storage of the new drug substance. They can 
be  identified  or  unidentified,  volatile  or  non-volatile,  and 
include: 
·  Starting materials 
·  By-products 
·  Intermediates 
·  Degradation products 
·  Reagents, ligands and catalysts 
Inorganic  impurities  can  result  from  the  manufacturing 
process.  They  are  normally  known  and  identified  and 
include: 
·  Reagents, ligands and catalysts 
·  Heavy metals or other residual metals 
·  Inorganic salts 
·  Other materials (e.g., filter aids, charcoal) 
Actual and  potential impurities  most  likely  to  arise  during 
synthesis, purification and storage of the new drug substance 
should be identified, based on a sound scientific appraisal of 
the chemical reactions involved in the synthesis, impurities 
associated  with  raw  materials  that  could  contribute  to  the 
impurity  profile  of  the  new  drug  substance,  and  possible 
degradation products. This discussion can be limited to those 
impurities  that  might  reasonably  be  expected  based  on 
knowledge of the chemical reactions and conditions involved. 
Guided  by  existing  genotoxicity  data  or  the  presence  of 
structural  alerts,  potential  genotoxic  impurities  should  be 
identified.  When  a  potential  impurity  contains  structural 
alerts,  additional  genotoxicity  testing  of  the  impurity, 
typically  in  a  bacterial  reverse  mutation  assay,  should  be 
considered.  While  according  to  the  Q3A  guideline  such 
studies  can  usually  be  conducted  on  the  drug  substance 
containing  the  impurity  to  be  controlled,  studies  using 
isolated  impurities  are  much  more  appropriate  for  this 
purpose and highly recommended.  
Drug  products  should  contain  no  higher  levels  of  residual 
solvents than can be supported by safety data. Some solvents 
that  are  known  to  cause  unacceptable  toxicities  (Class  1) 
should  be  avoided  in  the  production  of  drug  substances, 
excipients, or drug products unless their use can be strongly 
justified  in  a  riskbenefit  assessment.  Some  solvents 
associated  with  less  severe  toxicity  (Class  2)  should  be 
limited  in  order  to  protect  patients  from  potential  adverse 
effects. Ideally, less toxic solvents (Class 3) should be used 
where  practical.  For  determination  of  acceptable  levels  of 
exposure to genotoxic carcinogens considerations of possible 
mechanisms of action and of the dose-response relationship 
are important components. Based on the above considerations 
genotoxic impurities may be distinguished into the following 
two classes: 
·  Genotoxic  compounds  with  sufficient  (experimental) 
evidence for a threshold related mechanism 
·  Genotoxic  compounds  without  sufficient  (experimental) 
evidence for a threshold-related mechanism 
Genotoxic  Compounds  with  Sufficient  Evidence  for  a 
Threshold-Related Mechanism 
Examples  of  mechanisms  of  genotoxicity  that  may  be 
demonstrated  to  lead  to  non-linear  or  thresholded  dose-
response  relationships  include  interaction  with  the  spindle 
apparatus  of  cell  division  leading  to  aneuploidy, 
topoisomerase  inhibition,  inhibition  of  DNA  synthesis, 
overloading of defence mechanisms, metabolic overload and 
physiological perturbations (e.g. induction of erythropoeisis, 
hyper-  or  hypothermia).  For  (classes  of)  compounds  with 
clear evidence for a thresholded genotoxicity, exposure levels 
which  are  without  appreciable  risk  of  genotoxicity.    This 
approach  calculates  a  “Permitted  Daily  Exposure”  (PDE), 
which is derived from the NOEL, or “the lowest to observed 
effect  level”  (LOEL)  in  the  most  relevant  (animal)  study 
using “uncertainty factors” (UF). 
Genotoxic Compounds without Sufficient Evidence for a 
Threshold-Related Mechanism 
The assessment of acceptability of genotoxic impurities for 
which no threshold mechanisms are identified should include 
both  pharmaceutical  and  toxicological  evaluations.  In 
general, pharmaceutical measurements should be guided by a 
policy  of  controlling  levels  to  “as  low  as  reasonably 
practicable”  (ALARP  principle),  where  avoiding  is  not 
possible. Levels considered being consistent with the ALARP 
principle  following  pharmaceutical  assessment  should  be 
assessed for acceptability from a toxicological point of view 
(see  decision  tree  &  following  sections).  If  the  level  of  a 
mutagenic impurity is  below the threshold of toxicological 
concern (equivalent to a clinical dose ≤ 1.5μg/day) it is not 
necessary  to  apply  ALARP  considerations  unless  it  is  a 
structure of very high concern, e.g. N-nitroso compounds
2,6. 
PHARMACEUTICAL VALUATION 
A specific discussion on impurities should be provided in the 
application  with  regard  to  impurities  with  potential 
genotoxicity.  A  rationale  of  the  proposed 
formulation/manufacturing strategy should be provided based 
on  available  formulation  options  and  technologies.  The 
applicant should highlight, within the chemical process and 
impurity profile of active substance, all chemical substances, 
used as reagents or present as intermediates, or side-products, 
known  as  genotoxic  and/or  carcinogenic  (e.g.  alkylating 
agents). More generally, reacting substances and substances 
which  show  “alerting  structure”  in  terms  of  genotoxicity 
which  are  not  shared  with  the  active  substance.  Potential 
alternatives  which do not lead to genotoxic residues in the 
final  product  should  be  used  if  available.  A  justification 
needs  to  be  provided  that  no  viable  alternative  exists, 
including  alternative  routes  of  synthesis  or  formulations, 
different starting materials. This might for instance include Sunil et al. IRJP 2012, 3 (4) 
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cases  where  the  structure,  which  is  responsible  for  the 
genotoxic and/or carcinogenic potential, is equivalent to that 
needed  in  chemical  synthesis.  If  a  genotoxic  impurity  is 
considered to be unavoidable in a drug substance, technical 
efforts  (e.g.  purification  steps)  should  be  undertaken  to 
reduce  the  content  of  the  genotoxic  residues  in  the  final 
product in compliance with safety needs or to a level as low 
as  reasonably  practicable  (see  safety  assessment).  Data  on 
chemical  stability  of  reactive  intermediates,  reactants,  and 
other  components  should  be  included  in  this  assessment. 
Detection and/or quantification of these residues should be 
done by state-of-the-art analytical techniques
5. 
TOXICOLOGICAL ASSESSMENT 
The impossibility of defining a safe exposure level (zero risk 
concept) for genotoxic carcinogens without a threshold and 
the  realization  that  complete  elimination  of  genotoxic 
impurities  from  drug  substances  is  often  unachievable, 
requires implementation of a concept of an acceptable risk 
level, i.e. an estimate of daily human exposure at and below 
which there is a negligible risk to human health. However, 
these approaches require availability of adequate data from 
long-term  carcinogenicity  studies.  In  most  cases  of 
toxicological assessment of genotoxic impurities only limited 
data from in vitro studies with the impurity (e.g. Ames test, 
chromosomal  aberration  test)  are  available  and  thus 
established approaches to determine acceptable intake levels 
cannot be applied. Calculation of “safety multiples” from in 
vitro data (e.g. Ames test) are considered inappropriate for 
justification  of  acceptable  limits.  Moreover,  negative 
carcinogenicity and genotoxicity data with the drug substance 
containing  the  impurity  at  low  ppm  levels  do  not  provide 
sufficient  assurance  for  setting  acceptable  limits  for  the 
impurity  due  to  the  lack  of  sensitivity  of  this  testing 
approach. Even  potent  mutagens and  carcinogens are  most 
likely to remain undetected when tested as part of the drug 
substance,  i.e.  at  very  low  exposure  levels.  A  pragmatic 
approach  is  therefore  needed  which  recognises  that  the 
presence  of  very  low  levels  of  genotoxic  impurities  is not 
associated with an unacceptable risk
4. 
APPLICATION  OF  A  THRESHOLD  OF 
TOXICOLOGICAL CONCERN 
A  threshold  of  toxicological  concern  (TTC)  has  been 
developed  to  define  a  common  exposure  level  for  any 
unstudied  chemical that  will not  pose  a  risk  of  significant 
carcinogenicity  or other toxic effects. This TTC value was 
estimated  to  be  1.5μg/person/day.  The  TTC,  originally 
developed  as  a  “threshold  of  regulation”  at  the  FDA  for 
foodcontact materials was established based on the analysis 
of 343 carcinogens from a carcinogenic potency database and 
was  repeatedly  confirmed  by  evaluations  expanding  the 
database  to  more  than  700  carcinogens.  The  probability 
distribution of carcinogenic potencies has been used to derive 
an  estimate  of  a  daily  exposure  level  (μg/person)  of  most 
carcinogens which would give rise to less than a one in a 
million  (1  x  10-6)  upper  bound  lifetime  risk  of  cancer 
(“virtually  safe  dose”).  Further analysis  of  subsets  of  high 
potency carcinogens led to the suggestion of a 10-fold lower 
TTC  (0.15μg/day)  for  chemicals  with  structural  alerts  that 
raise  concern  for  potential  genotoxicity.  However,  for 
application of a TTC in the assessment of acceptable limits of 
genotoxic impurities in drug substances a value of 1.5μg/day, 
corresponding  to  a  10-5  lifetime  risk  of  cancer  can  be 
justified as for pharmaceuticals a benefit exists. It should be 
recognized in this context that the methods on which the TTC 
value  is  based,  are  generally  considered  very  conservative 
since  they  involved  a  simple  linear  extrapolation  from  the 
dose giving a 50% tumour incidence (TD50) to a 1 in 106 
incidence, using TD50 data for the most sensitive species and 
most sensitive site (several “worst case” assumptions). Some 
structural groups were identified to be of such high potency 
that intakes even below the TTC would be associated with a 
high probability of a significant carcinogenic risk. This group 
of high potency genotoxic carcinogens comprises aflatoxin-
like-,  Nnitroso-,  and  azoxy-compounds  that  have  to  be 
excluded  from  the  TTC  approach.  Risk  assessment  of 
members of such groups requires compound-specific toxicity 
data. 
There may be reasons to deviate from the TTC value based 
on the profile of genotoxicity results. Positive result from in 
vitro  studies  only  may  allow  to  exempt  an  impurity  from 
limitation at TTC level if lack  of in vivo relevance of the 
findings is convincingly demonstrated based on a weight-of 
evidence approach (see ICH S2 guidelines). This approach 
will  usually  need  negative  results  with  the  impurity  from 
some additional in vitro and/or appropriate in vivo testing. A 
TTC value higher than 1.5μg/day may be acceptable under 
certain conditions, e.g. short-term exposure, for treatment of 
a life-threatening condition, when life expectancy is less than 
5  years,  or  where  the  impurity  is  a  known  substance  and 
human  exposure  will  be  much  greater  from  other  sources 
(e.g.  food).  Genotoxic  impurities  that  are  also  significant 
metabolites may be assessed based on the acceptability of the 
metabolites.  The  concentration  limits  in  ppm  of  genotoxic 
impurity  in  drug  substance  derived  from  the  TTC  can  be 
calculated  based  on  the  expected  daily  dose  to  the  patient 
using equation: 
 
Concentration limit (ppm) = TTC [μg/day] / dose [g/day] 
 
The TTC concept should not be applied to carcinogens where 
adequate toxicity data (long-term studies) are available and 
allow for a compound-specific risk assessment. It has to be 
emphasized  that  the  TTC  is  a  pragmatic  risk  management 
tool  using  a  probabilistic methodology,  i.e.  there is  a high 
probability  that  a  10-5  lifetime  cancer  risk  will  not  be 
exceeded  if  the  daily  intake  of  a  genotoxic  impurity  with 
unknown  carcinogenic  potential/potency  is  below  the  TTC 
value.  The  TTC  concept  should  not  be  interpreted  as 
providing absolute certainty of no risk
2,7. 
CONCLUSION 
Genotoxic compounds have the potential to damage DNA at 
any  level  of  exposure  and  that  such  damage  may 
lead/contribute to tumour development. Thus for genotoxic 
carcinogens  it  is  prudent  to  assume  that  there  is  no 
discernible threshold and that any level of exposure carries a 
risk.    A  TTC  value  of  1.5μg/day  intake  of  a  genotoxic 
impurity  is  considered to  be  associated  with  an  acceptable 
risk (excess cancer risk of <1 in 100,000 over a lifetime) for 
most pharmaceuticals. From this threshold value, a permitted 
level in the active substance can be calculated based on the 
expected daily dose. 
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